Vyome Holdings Inc (HIND)

Form 8-K - Current report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Vyome Presents Transformational VT-1953 Phase 2 Clinical Study Data at Prestigious AACR 2026

VT-1953 topical gel significantly reduced MFW-associated severe malodor over a 14 Day period (P=0.0020) as scored by investigators. VT-1953...

Vyome to Present Compelling Phase 2 Clinical Data on VT-1953 for Treatment of MFW at AACR 2026

Complete Phase 2 clinical data on the efficacy and safety of VT-1953 in MFW patients accepted for presentation at the annual meeting of the...

Form DEF 14A - Other definitive proxy statements

Vyome Reports Transformational 2025 Results: Company Well Positioned for Breakout Phase

Completed a streamlined Nasdaq listing through a merger transaction, with a common stock capital structure and no preferred stock or debt...

Form PRE 14A - Other preliminary proxy statements

Form 8-K - Current report

Livechain Completes Acquisition of Senior, Secured Debt of Humanyze, An MIT Incubated, AI Enabled HR Analytics Company

Livechain Creates Path to Seek Potential Uplisting to National Exchange in 2026 Livechain, Inc. (“Livechain”) (OTCX: LICH), a subsidiary of Vyome...

Vyome Announces the Publication of Positive Preclinical Results in Uveitis, Addressing a $3B Potential Market Opportunity

VT-1908 was demonstrated to be effective as a topical steroid in the uveitis preclinical model and shows very good safety Plans to generate...

Vyome Files for VT-1953 Orphan Drug Status, Furthers Strategic Focus On VT-1953 Program Over the Next 6 Months

Acceptance of Orphan Drug Status would confer certain anticipated US Market Exclusivity, R&D tax benefits, and PDUFA fee waiver of...

Vyome Successfully Capitalizes All VT-1953 Funding Requirements For Initial Phase 3 Results

Company Chose Minimal Dilution Path with No Warrants and Has Sufficient Liquidity to Deliver Initial Phase 3 Results for MFW product Vyome...

Form 8-K - Current report

Independent Analyst Values Vyome’s VT-1953 at USD 1 Billion Upon Successful Completion of Phase 3 Study

Third-party analysis estimates the total addressable U.S. market to be approximately USD 2.2 billion Modeled peak annual U.S. sales approaching...